Another approach is to target hyperactivated oncogenic pathways that regulate the expression or activity of anti-apoptotic BCL2 proteins (e.g., MAPK or PI3K pathways), thereby specifically targeting cancer cells (47–50). Here, BCL2 is linked to cancer.